Abstract

Ethical and Regulatory Implications of Sourcing Drug X During an FDA-Reported Shortage: 503A vs. 503B Compounding Facilities

Author(s): Asbill Hayden R, Moore W Mark, Asbill Scott

Issue: Mar/Apr 2026 - Volume 30, Number 2

Page(s): 120-129

Download in electronic PDF format for $75
  • Ethical and Regulatory Implications of Sourcing Drug X During an FDA-Reported Shortage: 503A vs. 503B Compounding Facilities Page 1
  • Ethical and Regulatory Implications of Sourcing Drug X During an FDA-Reported Shortage: 503A vs. 503B Compounding Facilities Page 2
  • Ethical and Regulatory Implications of Sourcing Drug X During an FDA-Reported Shortage: 503A vs. 503B Compounding Facilities Page 3
  • Ethical and Regulatory Implications of Sourcing Drug X During an FDA-Reported Shortage: 503A vs. 503B Compounding Facilities Page 4
  • Ethical and Regulatory Implications of Sourcing Drug X During an FDA-Reported Shortage: 503A vs. 503B Compounding Facilities Page 5
  • Ethical and Regulatory Implications of Sourcing Drug X During an FDA-Reported Shortage: 503A vs. 503B Compounding Facilities Page 6
  • Ethical and Regulatory Implications of Sourcing Drug X During an FDA-Reported Shortage: 503A vs. 503B Compounding Facilities Page 7
  • Ethical and Regulatory Implications of Sourcing Drug X During an FDA-Reported Shortage: 503A vs. 503B Compounding Facilities Page 8
  • Ethical and Regulatory Implications of Sourcing Drug X During an FDA-Reported Shortage: 503A vs. 503B Compounding Facilities Page 9
  • Ethical and Regulatory Implications of Sourcing Drug X During an FDA-Reported Shortage: 503A vs. 503B Compounding Facilities Page 10

Abstract

In the case of an FDA shortage of drug X, an injectable medication, the safer route to supply the drug to hospital systems would be through a 503B outsourcing facility. Unlike 503A pharmacies, 503B outsourcing facilities are permitted to compound medications in larger batches and are held to stricter FDA oversight. They must comply with current good manufacturing practices (cGMP), which help ensure the quality of medications intended for broader distribution during drug shortages in hospital systems.

Related Keywords

  • Drug shortages
  • FDA regulations

Related Categories

  • UNITED STATES PHARMACOPEIA CONVENTIONS
  • FDA

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Mar/Apr 2026
Pg. 120-129
Ethical and Regulatory Implications of Sourcing Drug X During an FDA-Reported Shortage: 503A vs. 503B Compounding Facilities
Author(s): Asbill Hayden R, Moore W Mark, Asbill Scott
Jul/Aug 2022
Pg. 298-301
The Role of Compounding Pharmacists During Drug Shortages
Author(s): Ofei Kelvin
Nov/Dec 2012
Pg. 456-460
Drug Shortage Compounding: The Only Safe Medication Source in a Time of Crisis
Author(s): Lyon Joanna
Mar/Apr 2014
Pg. 117-118
IACP's Continuing Support of Compounding Pharmacists: Letter to the FDA Concerning 503B Outsourcing Facilities
Author(s): Miller David G
Mar/Apr 2022
Pg. 100-109
Allowing Compounding Pharmacies to Address Drug Shortages
Author(s): Broughel James
Jul/Aug 2012
Pg. 294-298
Drug Shortages & Discontinued Drugs: The Effects on Patients and Healthcare Providers
Author(s): Allen Loyd V Jr, Williams LaVonn A
Jan/Feb 2025
Pg. 22-27
Best Practices When Compounding FDA-Approved Drugs Listed in Shortage
Author(s): Alliance for Pharmacy Compounding
May/Jun 2013
Pg. 180
PreScription: Compounding for Drug Shortages
Author(s): Allen Loyd V Jr
Mar/Apr 2011
Pg. 92
PreScription: Discontinued Drugs and Drug Shortages
Author(s): Allen Loyd V Jr
Jul/Aug 2012
Pg. 350-351
PostScription: Drug Shortages and Discontinued Drugs: Their Effects on Healthcare
Author(s): Allen Loyd V Jr, Williams LaVonn A
Nov/Dec 2006
Pg. 446-448
Basics of Compounding for Hazardous Drugs, Part 2: Regulation and Sources of Contamination
Author(s): Allen Loyd V Jr
May/Jun 2023
Pg. 180
PreScription: Shortages Continue--Compounding Pharmacies Fill the Gap…Again!
Author(s): Allen Loyd V Jr
Sep/Oct 2015
Pg. 377-380
The Evolution of 21 CFR Parts 210 & 211 for Drug Compounders: An Unspoken Opportunity for Pharmacists
Author(s): Parks Kenneth Chase, Bernard Brian, Cogdill Christopher Blake
May/Jun 2021
Pg. 206-209
FDA-funded Report on Compounded Hormones is Tainted, Analysis Shows
Author(s): Brunner Scott
Jan/Feb 2026
Pg. 6-11
Between Necessity and Compliance: Understanding FDA’s GFI #256 for Animal Drug Compounding
Author(s): Vogel Jordan T, Howard Brad
Sep/Oct 2014
Pg. 379-380
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A
Author(s): Blankenship Cynthia E
Jul/Aug 2012
Pg. 268
PreScription: Drug Shortages and Discontinued Drugs
Author(s): Allen Loyd V Jr
Sep/Oct 2021
Pg. 358-362
Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA
Author(s): Cabaleiro Joe
Mar/Apr 2023
Pg. 92
PreScription: Amoxicillin Shortage Continues: Compounding Pharmacies Filling the Gap!
Author(s): Allen Loyd V Jr
Sep/Oct 2017
Pg. 356
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Author(s): Allen Loyd V Jr